I Lost 41 Pounds on Zepbound. My Arms Still Look Like My Grandmother’s. Here’s What I Wasn’t Told

You did the hard part. You stuck the needle in every week. You white-knuckled through the nausea. You watched the number drop, and drop, and keep dropping, and somewhere around pound thirty you let yourself believe the thing you’d wanted to believe for years: this is finally working.

And then you’re standing in a fitting room at Kohl’s, holding a dress that fit at your goal weight, and it hangs wrong. Not in the hips. Not in the waist. In the arms. They’re smaller, sure — but smaller in a way that looks less like “toned” and more like “deflated.” Loose in a way they never were before, even when you weighed more.

You don’t say anything about it out loud. You tell your friends the weight loss has been amazing, because it has been. You just also, privately, stopped wearing sleeveless tops. And you’re maybe a little afraid to bring it up with your doctor, because what if she hears “I feel weak and my arms look strange” as “I’m ungrateful that the drug worked”?

Here’s the thing nobody handed you a pamphlet about: that’s not ingratitude. It’s not aging. It’s not your imagination. It has a name, a mechanism, and — this is the part that matters — a fix that has nothing to do with willpower and everything to do with a training habit you were never told you needed.

What’s actually happening in your body

When you lose weight on a GLP-1 drug like Zepbound, you’re not losing pure fat. A meaningful chunk of that loss is lean mass — muscle, plus some organ tissue and water. The exact number moves around depending on the drug and the study, but the range shows up again and again: the tirzepatide substudy of SURMOUNT-1 found roughly a quarter of total weight lost was lean mass, while a 2024 meta-analysis of 22 randomized trials put the figure at about 25%, and a recent case-series review noted lean tissue can account for anywhere from 26% to 40% of what comes off, with some semaglutide trials running even higher. A 2024 review in Circulation put semaglutide’s lean-mass share as high as 40% in some analyses.

That’s a wide range, and the honest answer is researchers are still sorting out why some people lose a little lean mass and others lose a lot — but the pattern that keeps surfacing is this: the people who lose the least muscle are the ones who were resistance training and eating enough protein while they lost the weight, not after.

Here’s the part that finally explains the mirror. Fat sits under the skin of your upper arm and gives it shape and firmness from the outside. Muscle gives the arm its structure from underneath. When you lose both — a lot of fat, plus a slice of muscle — you don’t end up with a smaller version of a toned arm. You end up with skin that’s lost its filler on both sides, with nothing pulling it taut. That’s the “deflated” look. It’s not a flaw in how you did this. It’s what happens when a drug is asked to do a job — appetite suppression — that it does very well, while nothing is asked to do the other job: telling your body which tissue to protect on the way down.

“But isn’t lifting weights just vanity at this point?”

No — and this is worth sitting with for a second. Muscle isn’t just how your arms look in a sleeveless dress. It’s your resting metabolic engine, your blood sugar buffer, and — this is the one that should actually worry you — the single biggest lever you have against regaining this weight as fat instead of muscle if life ever knocks you off the medication. Skipping resistance training didn’t cost you the number on the scale. It cost you the composition of the number. That’s a fixable problem, not a permanent verdict.

A week that actually accounts for a suppressed appetite

The generic advice — “add strength training” — isn’t wrong, it’s just useless without the logistics. Here’s what the research on GLP-1 users and resistance training actually supports:

Frequency: Two to three sessions a week is enough to matter. A case series on patients who prioritized lean tissue during semaglutide and tirzepatide treatment found that people who trained 3–5 days a week and lifted deliberately not only preserved lean mass but in some cases gained it back while still losing weight overall.

What to do: Compound movements — squats, rows, push-ups, presses, deadlift variations — recruit more muscle per session than isolation moves, which matters when your energy and appetite are both limited.

Protein, the part everyone skips over: The range that shows up consistently across nutrition research on GLP-1 users is 1.2 to 1.6 grams of protein per kilogram of body weight per day, split fairly evenly across meals rather than loaded into one. For a 165-pound woman, that’s roughly 90–120 grams a day — which sounds enormous until you realize most people on GLP-1s are eating closer to half that, according to a 2025 study that measured actual intake in GLP-1 users and found the average person hit barely 43% of their target.

Timing around nausea: This is the piece almost nobody says out loud. If injection day or the day after tends to flatten your appetite, that’s not your training day — it’s your recovery day. Put your heavier session on the day before your injection, or whenever your appetite is most reliable, so you can actually eat enough afterward to make the workout count. A 35-minute session doesn’t need to be elaborate. It needs to happen on a day you can fuel it.

Objection: “I already tried this and quit.”

If you did one beginner YouTube video, felt nauseated, and never went back — that’s not a strength-training failure. That’s a sequencing problem. You tried to build a new habit on the one day your body had the least capacity to support it. Move the session, not the goal, and it stops feeling like punishment.

Tapering: the part everyone treats like a cliff edge

If you’re thinking about eventually coming off Zepbound — or you’re worried about what happens if you have to — the research here is more encouraging than the internet panic suggests, but it does require planning. In SURMOUNT-4, people who stopped tirzepatide abruptly and switched to placebo regained an average of 14% of their lost weight within a year. A study of gradual semaglutide tapering over nine weeks, paired with continued coaching on diet and exercise, found weight stayed essentially stable for the people who followed through — a very different outcome from stopping cold. Longer-term data adds real hope here too: an Epic Research analysis of nearly 190,000 patients found that two years after stopping, more than half of tirzepatide users had maintained or continued to lose weight.

None of this is a do-it-yourself dosing plan — any tapering schedule needs to happen with your prescriber, not around them. But the takeaway is worth carrying with you: tapering is a phase you can plan for, not a cliff you fall off. And the muscle you build now is exactly what makes that phase survivable, because a body with more muscle burns more at rest and has more room to absorb a dip in medication without the fat immediately creeping back.

What this actually is

Rebuilding muscle at 44 isn’t vanity, and it isn’t a confession that the drug failed you. The drug did what it does. Nobody told you it needed a partner. The loose feeling in your arms isn’t the final word on your body — it’s unfinished business, and it responds to the same two things it always has: consistent resistance work and enough protein to support it. You didn’t do this wrong. You just weren’t given the second half of the plan. Now you have it.